Background Chimeric antigen receptor (CAR) T cell therapies show remarkable progress in treating liquid tumors, with a complete remission rate of over 57%.1 Translating the success of CAR T cells to solid tumors will need an understanding of the key mechanisms responsible for the cytotoxicity of CAR T cells. The primary factors contributing to tumor resistance against CAR T therapies are widely contested2, therefore, we seek to explore the impact of different CAR T cell killing mechanisms of tumors.
Methods We examine CAR T cell killing of a leukemic cell line, NALM6, and an ovarian cancer cell line, SkOV3-CD19, in the presence of Granzyme B inhibitors and a Fas ligand inhibitor. We develop a fluorescent membrane reporter that translocates to the nucleus upon specific proteolytic cleaving by Granzyme A and B.
Overexpressing native Granzyme B inhibitor, Protease Inhibitor-9 (PI-9), in NALM6 and SkOV3-CD19 does not affect killing frequencies in CAR(19-41BBζ and 19-28ζ) T cell cytotoxicity assays.
Treating 19-41BBζ with a small molecule inhibitor of Granzyme B does not impact killing frequencies in cytotoxicity assays against NALM6 and SkOV3-CD19.
Overexpressing PI-9 in NALM6 and SkOV3-CD19 does not affect 19-41BBζ CAR T killing frequencies or killing kinetics in single cell time-lapse assays.
Inhibition of Fas ligand on 19-41BBζ CAR T cells does not impact killing frequencies against NALM6 and SkOV3-CD19.
Conclusions Our findings suggest that suppressing Granzyme B activity with small molecules or native proteins does not impair killing frequencies of 19-41BBζ CAR T cells en masse or at the single cell level. We hypothesize that Granzyme A facilitates CAR T killing in the absence of Granzyme B, implying redundancy in granzyme expression. This study provides a comprehensive understanding of the main mechanisms associated with CAR T cell-mediated killing.
Xu X, Huang S, Xiao X, Sun Q, Liang X, Chen S, Zhao Z, Huo Z, Tu S and Li Y. Challenges and clinical strategies of CAR T-cell therapy for acute lymphoblastic leukemia: overview and developments. Front Immunol. 2021; 11:569117.
Shah NN, Fry TJ. Mechanisms of resistance to CAR T cell therapy. Nat Rev Clin Oncol. 2019;16(6):372–385.
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.